NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/27/2022
Back to search
Official data from USPTO
EG 427 PINPOINT GENE THERAPY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
12/27/2022
Trademark type
Combined
Nice classes
1, 5, 10
Filing date
06/24/2021
Registration date
12/27/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/27/2022
Last transaction
12/27/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
34
Owner location
PARIS, FR
Examiner
JARAMILLO, JAVIER R
Law office
M70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the terms "EG 427" formed from a series of dots above the stylized words "PINPOINT GENE THERAPY".
Holders and representatives
Holders
EG427
GENELPIS
Representatives
Pina Campagna CARTER, DELUCA AND FARRELL LLP
Technical classification
Nice Classes
Class 1Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical and biochemical preparations for scientific and research purposes; reagents for scientific and research purposes; chemical preparations and chemical reagents for industrialagri-foodcosmeticpharmaceutical and environmental purposesother than for medical or veterinary use; Stem cells for research purposes; Bacterialbacteriologicalbiological and chemical preparations for scientific purposes other than for medical or veterinary use
Class 5
Pharmaceutical preparations for use as treatments of neurological pathologies; biological tissue cultures for medical purposes; albuminous preparations for medical purposes; chemical preparations for use as treatments of neurological pathologies; Chemical and biological reagents for medicalpharmaceutical or veterinary purposes; reagents and culture media for in vitro medicalpharmaceutical or veterinary diagnosis; Pharmaceutical preparations for human use for the treatment of neurological pathologies; Bacterialbacteriologicalbiological and chemical preparations for medical and therapeutic purposesfor treatment of neurological pathologies
Class 10
Surgical apparatus and instruments for medical or veterinary use; therapeutic and assistive devices to diagnose or administer treatments for cardiovasculardigestiveendocrinegenitourinarygenetichematologicalimmuneinfectiousneurologicaloncologicrespiratorysighthearingpulmonary and skin diseasesdesigned for people with disabilities; In vitro diagnostic apparatus and instruments for medicalpharmaceutical or veterinary use in the field of gene therapy for diagnosis of cardiovasculardigestiveendocrinegenitourinarygenetichematologicalimmuneinfectiousneurologicaloncologicrespiratoryskin diseases
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/27/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/11/2022
PUBO
PUBLISHED FOR OPPOSITION
10/11/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/21/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
09/07/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
09/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/26/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/23/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/22/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/22/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/25/2022
GNRT
NON-FINAL ACTION E-MAILED
03/25/2022
CNRT
NON-FINAL ACTION WRITTEN
03/25/2022
DOCK
ASSIGNED TO EXAMINER
03/16/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
02/04/2022
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
09/09/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/08/2021
NWAP
NEW APPLICATION ENTERED
06/28/2021
Continuous trademark protection
Get notified about every new filing that threatens EG 427 PINPOINT GENE THERAPY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.